scholarly journals A human monoclonal antibody specific to placental alkaline phosphatase, a marker of ovarian cancer

mAbs ◽  
2013 ◽  
Vol 6 (1) ◽  
pp. 86-94 ◽  
Author(s):  
Niccolò Ravenni ◽  
Marcel Weber ◽  
Dario Neri
Keyword(s):  
Ovarian Cancer ◽  
Monoclonal Antibody ◽  
Alkaline Phosphatase ◽  
Human Monoclonal Antibody ◽  
Placental Alkaline Phosphatase

scholarly journals Practical Applications of a Monoclonal Antibody (NDOG2) against Placental Alkaline Phosphatase in Ovarian Cancer

1985 ◽  
Vol 78 (11) ◽  
pp. 899-905 ◽  
Author(s):  
J O Davies ◽  
P Jackson ◽  
C Sadowski ◽  
E R Davies ◽  
E Pitcher ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Monoclonal Antibody ◽  
Alkaline Phosphatase ◽  
Imaging Techniques ◽  
False Negative ◽  
Enzymic Activity ◽  
Response To Therapy ◽  
Immunoperoxidase Technique ◽  
Placental Alkaline Phosphatase ◽  
Ovarian Carcinomas

A monoclonal antibody (NDOG2) against placental alkaline phosphatase (PLAP) in ovarian cancer has been used in three ways by the Bristol University Department of Obstetrics & Gynaecology. First, in an indirect immunoperoxidase technique, NDOG2 demonstrated positive standing in 64% of 56 ovarian carcinomas as well as in 25% of 44 benign tumours. The majority of these positive tumours were serous cystadenocarcinomas or serous cystadenomas and there was considerable variation in the expression of this antigen from tumour to tumour. NDOG2 was also used as the basis of two serum assays and, when labelled with 123-iodine (123I), in radioimmunoscintigraphy (RIS) to monitor patients' response to therapy. The first serum assay measures the enzymic activity of PLAP and the second recognizes the antigenicity of the molecules. Assay 2 proved more useful in that it predicted the course of the disease in 45% of patients followed up, whereas Assay 1 was only of use in 25% of cases. RIS proved to be a useful imaging technique and was at least as sensitive as conventional imaging techniques. The common causes of false-positive and false-negative results are described.

Use of monoclonal antibodies to detect human placental alkaline phosphatase.

1983 ◽  
Vol 29 (1) ◽  
pp. 115-119 ◽  
Author(s):  
G De Groote ◽  
P De Waele ◽  
A Van de Voorde ◽  
M De Broe ◽  
W Fiers
Keyword(s):  
Monoclonal Antibody ◽  
Alkaline Phosphatase ◽  
Monoclonal Antibodies ◽  
Solid Phase ◽  
Enzymatic Reactions ◽  
Placental Alkaline Phosphatase ◽  
Human Placental Alkaline Phosphatase ◽  
Human Sera ◽  
Starch Gel ◽  
Alkaline Phosphatase Isoenzyme

Abstract Convenient, sensitive, and specific solid-phase immunoassays involving monoclonal antibody are described for the determination of human placental alkaline phosphatase (hPLAP). An endogenous enzyme immunoassay combined the specificity of the immunological and the enzymatic reactions. Alternatively, a solid-phase "sandwich" radioimmunoassay involving immobilized polyclonal rabbit anti-hPLAP in combination with iodinated monoclonal antibody provided some additional advantages. Both tests can be used to detect hPLAP from various sources, e.g., in human sera during pregnancy or as a tumor marker. The radioimmunoassay detected an increase in hPLAP at nine weeks of gestation. We discuss the use of monoclonal antibodies for the differentiation of different alkaline phosphatase isoenzyme types by electrophoresis on starch gel.

A Potential Use of a Monoclonal Antibody to Placental Alkaline Phosphatase (PLAP) to Detect Lymph Node Metastases of Seminoma

1996 ◽  
Vol 155 (1) ◽  
pp. 337-341 ◽  
Author(s):  
Kiyoshi Koshida ◽  
Tadao Uchibayashi ◽  
Hajime Yamamoto ◽  
Kunihiko Yokoyama ◽  
Kazuyuki Hirano
Keyword(s):  
Monoclonal Antibody ◽  
Alkaline Phosphatase ◽  
Lymph Node ◽  
Lymph Node Metastases ◽  
Placental Alkaline Phosphatase ◽  
Node Metastases ◽  
Potential Use

HMOCC-1, a human monoclonal antibody that inhibits adhesion of ovarian cancer cells to human mesothelial cells

2004 ◽  
Vol 95 (2) ◽  
pp. 290-298 ◽  
Author(s):  
Nao Suzuki ◽  
Daisuke Aoki ◽  
Yutaka Tamada ◽  
Nobuyuki Susumu ◽  
Kimiko Orikawa ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Monoclonal Antibody ◽  
Cancer Cells ◽  
Human Monoclonal Antibody ◽  
Mesothelial Cells ◽  
Ovarian Cancer Cells

Comparison of CA 125 and Placental Alkaline Phosphatase as Ovarian Tumor Markers

1987 ◽  
Vol 73 (3) ◽  
pp. 301-302 ◽  
Author(s):  
Pentti K. Heinonen ◽  
Olli-Pekka Kallioniemi ◽  
Timo Koivula
Keyword(s):  
Ovarian Cancer ◽  
Alkaline Phosphatase ◽  
Tumor Marker ◽  
Cancer Patients ◽  
Tumor Markers ◽  
Ovarian Tumor ◽  
Serum Levels ◽  
Ca 125 ◽  
Placental Alkaline Phosphatase ◽  
Serum Concentrations

The serum concentrations of CA 125 and placental alkaline phosphatase were analyzed in 16 patients with ovarian cancer. Increased serum levels of CA 125 and placental alkaline phosphatase were observed in 75% and 50% of the cancer patients, respectively. The serum levels of these tumor markers were not correlated, supporting their distinct antigenic nature. CA 125 seems to be a more promising tumor marker for ovarian cancer than placental alkaline phosphatase.

Sign in / Sign up

Export Citation Format

Share Document